Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deep learning-based treatment decision support framework for multi-vessel coronary artery disease using integrated coronary angiography and clinical data.

BMC medical informatics and decision making·2026
Same author

Effects of Expected Progeny Difference and Feeding Systems on Carcass Characteristics in Hanwoo Steers.

Animals : an open access journal from MDPI·2026
Same author

One-Step Electrochemical Fabrication of Poly O-cresolphthalein Complexone and Electrochemically Reduced Graphene Oxide Modified Electrode for Detection of Nitrofurantoin.

Sensors (Basel, Switzerland)·2026
Same author

Patient-specific lung cancer tumoroids recapitulate the tumor microenvironments for functional evaluation of therapeutic responses and immune-stromal interactions.

Journal of translational medicine·2026
Same author

Dynamics of tumor ecosystems and microbiome in response to neoadjuvant ABFOLFOX treatment in patients with unresectable colorectal cancer with liver metastasis.

Genome medicine·2026
Same author

DDRL:Dyna-Based Discriminative Reinforcement Learning for Optimizing Sepsis Treatment Pathways in Offline Environments.

IEEE journal of biomedical and health informatics·2026

Related Experiment Video

Updated: Mar 1, 2026

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.6K

Annotation-free prediction of immunotherapy response in melanoma using single-cell transcriptomic data.

Da Eun Oh1,2, Gaeun Kee3,4, Ji-Hye Oh1

  • 1Bioinformatics Core Laboratory, Convergence Medicine Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea.

Plos One
|February 27, 2026
PubMed
Summary

An artificial intelligence model predicts immune checkpoint inhibitor response in melanoma using single-cell RNA sequencing data. This approach identifies novel biomarkers like CCR7, improving patient stratification for personalized immunotherapy.

More Related Videos

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors
06:32

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors

Published on: August 18, 2023

3.1K
Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
07:46

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

5.6K

Related Experiment Videos

Last Updated: Mar 1, 2026

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.6K
Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors
06:32

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors

Published on: August 18, 2023

3.1K
Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
07:46

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

5.6K

Area of Science:

  • Oncology
  • Immunology
  • Bioinformatics

Background:

  • Immune checkpoint inhibitors (ICIs) have revolutionized advanced melanoma treatment, but response prediction remains challenging due to tumor heterogeneity.
  • Existing biomarkers like PD-L1 and tumor mutational burden have limited predictive accuracy for melanoma.
  • There is a critical need for novel biomarkers to identify patients likely to benefit from ICIs.

Purpose of the Study:

  • To develop and validate an artificial intelligence (AI)-based model for predicting ICI responsiveness in melanoma using single-cell RNA sequencing (scRNA-seq) data.
  • To identify novel predictive biomarkers for ICI response without requiring cell type annotation.
  • To explore the functional roles and clinical significance of identified biomarkers in melanoma.

Main Methods:

  • An AI model was trained on scRNA-seq data from 16,290 tumor-infiltrating cells in melanoma.
  • Multiple AI algorithms were evaluated, including Extreme Gradient Boosting, Random Forest, and Convolutional Neural Networks.
  • The best-performing model was validated using three independent bulk RNA-seq datasets.

Main Results:

  • The AI model achieved an area under the curve of 0.87 in predicting ICI response.
  • The model identified 29 predictive biomarkers, notably CCR7 and MTRNR2L2.
  • CCR7 was associated with favorable ICI response and improved survival, primarily expressed in B cells and memory T cells of responders.
  • MTRNR2L2 was linked to non-response and poorer outcomes, elevated in exhausted T cells of non-responders.
  • CCR7 expression was significantly associated with the immune molecular subtype of melanoma.

Conclusions:

  • AI-driven predictive modeling of unannotated scRNA-seq data is a robust approach for identifying clinically relevant biomarkers in melanoma.
  • The identified biomarkers, particularly CCR7, offer potential for improved patient stratification and personalized immunotherapy strategies.
  • This approach facilitates a deeper understanding of the immune landscape in responders versus non-responders to ICI therapy.